Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive Factors

Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04739501

Enrollment

100

Registered

2021-02-04

Start date

2020-12-01

Completion date

2022-03-30

Last updated

2021-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cancer

Brief summary

Radiological response after trans arterial chemoembolization (TACE) is classified according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) to: complete response (CR) (disappearance of arterial enhancement), partial response (PR) ( at least a 30% decrease in the sum of diameters of viable enhancement), progressive disease (PD) (an increase of at least 20% in the sum of the diameters of viable enhancement, or appearance of new lesions), and stable disease (any cases that do not qualify for either partial response or progressive disease

Detailed description

POST-TACE response of treatment for cases of hepatocellular cancer

Interventions

PROCEDURETACE

Trans-arterial chemoembolization in patients with hepatocellular carcinoma

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to No maximum

Healthy volunteers

Inclusion criteria

Clinical history and examination with special stress on symptoms and signs of chronic liver disease with or without evidence of hepatic decompensation e.g. the presence of ascites and with or without evidence of complications e.g. jaundice spider naevi, bleeding varices, ascites, and lower limb edema. Laboratory findings in the form of raised bilirubin and liver enzymes, impaired coagulation profile, and/or low serum albumin. Abdominal ultrasonography revealing liver cirrhosis (coarse echopattern, attenuated hepatic veins, irregular outlines, hypertrophy of caudate lobe and/or shrunken liver, presence of focal hepatic) and presence of splenomegaly, ascites, or portal vein thrombosis (PVT).

Exclusion criteria

A patient who had surgical resection or liver transplantation Patients refuse to participate Hepatic focal lesion other than HCC

Design outcomes

Primary

Measure	Time frame	Description
Post_TACE hepatic cell failure	1 year	Frequency of liver cell failure in form of jaundice , coagulopathy and encephalopathy

Countries

Egypt

Contacts

Primary ContactAmany M Ahmed

mahranamany18@gmail.com01146457697

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026